Quibim is a healthtech company pioneering AI-powered imaging biomarkers for precision medicine. Its platform develops foundational AI models that analyze MRI, CT, and PET scans to extract quantitative, actionable insights, enabling precise characterization of disease phenotypes and prediction of patient outcomes across oncology, immunology, neurology, and metabolic disorders.
Quibim's technology bridges research, clinical practice, and drug development. The company has secured regulatory clearances across the US, EU, UK, and other regions, and operates over 170 installations worldwide, including at institutions such as Mass General Brigham and Stanford. It has formed strategic alliances with biopharma companies including Merck KGaA and Novartis, and a global partnership with Philips to integrate its AI models into MR scanners.
In January 2025, Quibim announced a $50M Series A led by Asabys and Buenavista, with participation from UI Investissements, GoHub Ventures, Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures, and others. The funding supports expansion of its imaging foundation models and global commercial growth.
With roots in Valencia, Spain and growing US operations, Quibim combines deep imaging-biomarker expertise with modern AI to advance precision medicine and support pharmaceutical R&D.